Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814016 · ClinicalTrials.gov registry record · Phase 2
A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05814016 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 41 participants.
The verdict
NCT05814016, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The main aim is to see if danavorexton can help improve people's breathing in the recovery room after abdominal surgery.
Interventions
- DRUG Placebo
- DRUG Danavorexton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2024-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05814016
The ClinicalTrials.gov registry entry for NCT05814016 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05814016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05814016 about?
NCT05814016 is a clinical study titled "A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery". The main aim is to see if danavorexton can help improve people's breathing in the recovery room after abdominal surgery.
What is the current status of trial NCT05814016?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-05-11. Estimated completion is 2024-09-25.
What interventions are being tested in trial NCT05814016?
The interventions under investigation include: Placebo (DRUG), Danavorexton (DRUG).
Who is sponsoring clinical trial NCT05814016?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.